← Calendar
Readoutin 45d
AstraZeneca — Dato-DXd
Phase 3 primary completion: A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer.
- Date
- Jan 2027
- Type
- Readout
- Indication
- Metastatic Non-small Cell Lung Cancer
Source ↗Add to calendar
Get told when this date moves
The weekly brief is free. Pro adds reminders 7 days and 1 day before.
More from AstraZeneca
May2027
Readoutin 165d
AstraZeneca — Trastuzumab deruxtecanPhase 3 primary completion: Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09).
Feb2027
Readoutin 76d
AstraZeneca — Zibotentan/DapagliflozinPhase 3 primary completion: Study to Investigate Efficacy, Safety, and Tolerability of Zibotentan/Dapagliflozin Compared to Dapagliflozin in Participants With Chronic Kidney Disease and High Proteinuria (ZENITH High Proteinuria).
Feb2027
Readoutin 76d
AstraZeneca — AnifrolumabPhase 3 primary completion: Phase 3 Study of Anifrolumab in Adult Patients With Active Proliferative Lupus Nephritis.
Feb2027
Readoutin 76d
AstraZeneca — PlaceboPhase 3 primary completion: A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of AZD0780 in Participants With Dyslipidaemia.
Jan2027
Readoutin 45d
AstraZeneca — DurvalumabPhase 3 primary completion: A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer.